Meeting Banner
Abstract #0370

Predicting Long Term Survival for Breast Cancer Patients by HR MAS Metabolic Profiling During Neoadjuvant Chemotherapy

Maria Dung Cao1, Beathe Sitter1, Tone Frost Bathen1, Per Eystein Lnning2,3, Steinar Lundgren1,4, Ingrid Susanne Gribbestad1

1Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; 2Department of Oncology, Haukeland University Hospital, Bergen, Norway; 3University of Bergen, Bergen, Norway; 4Department of Oncology, St.Olav University Hospital, Trondheim, Norway

HR MAS MR metabolic profiling was performed in paired samples from locally advanced breast cancer patients obtained pre (n=19) and post (n=19) doxorubicine treatment. PLSDA analysis of HR MAS spectra showed classification between patients with long time survival (≥5 years), and patients who died of cancer recurrence within 5 years. Our results suggest distinct metabolic profiles of these two patient groups. High tCho, most significant GPC, levels before treatment correlated to long time survival, while high glycine and lactate levels were associated with poorer outcome.